Importância do Diagnóstico Laboratorial no Síndrome de HELLP

O Síndrome de Hellp (S. Hellp) é uma situação clínica que surge aproximadamente em 10% dos casos de pré-eclâmpsia grave. É uma disfunção multiorgânica em que a tríade laboratorial que o caracteriza, H-hemólise, EL-elevated liver enzymes (enzimas hepáticos elevados) e LP-low platelets (trombocitopenia) permite efectuar e monitorizar correctamente o diagnóstico e tratamento aplicado. O S. Hellp pode surgir inicialmente numa fase mais lenta, em que se verificam níveis moderadamente elevados de desidrogenase láctica (LDH), trombocitopenia ligeira (100.000-150.000/ul) e diminuição da haptoglobina. Posteriormente, torna-se evidente a existência de disfunção hepática, pela elevação dos níveis séricos do aspartato amino transferase (AST) e alanina amino transferase (ALT), acompanhados de concentrações ainda mais elevadas de LDH e trombocitopenia grave (<50.000/ul). Surge a anemia hemolítica microangiopática e verificam-se igualmente alterações significativas da coagulação. Outras perturbações podem ocorrer, nomeadamente a nível renal, cardiovascular e respiratório.

Case for Diagnosis

A 27 year-old-man, with no known personal or familial history of disease, mentioned a 10-year history of asymptomatic groups of telangiectasias, with a Blaschko lines distribution on the right lateral aspect of the neck and asymptomatic. He denied any episodes of disease or drug intake that could be associated with the disease. Blood work had no changes, namely of liver enzymes or infectious serologies. The clinical diagnosis of Idiopathic Acquired Unilateral Nevoid Telangiectasia was made, an uncommon, benign vascular malformation. The patient declined doing a cutaneous biopsy or treatment with a cosmetic intent.

Liver Depurative Techniques: A Single Liver Transplantation Center Experience

In a liver transplant (LT) center, treatments with Prometheus were evaluated. The main outcome considered was 1 and 6 months survival. Methods. During the study period, 74 patients underwent treatment with Prometheus; 64 were enrolled,with a mean age of 51 13 years; 47men underwent 212 treatments (mean, 3.02 per patient). The parameters evaluated were age, sex, laboratorial (liver enzymes, ammonia) and clinical (model for end-stage liver disease and Child-Turcotte-Pugh score) data. Results. Death was verified in 23 patients (35.9%) during the hospitalization period, 20 patients (31.3%) were submitted to liver transplantation, and 21 were discharged. LT was performed in 4 patients with acute liver failure (ALF, 23.7%), in 7 patients with acute on chronic liver failure (AoCLF, 43.7%), and in 6 patients with liver disease after LT (30%). Seven patients who underwent LT died (35%). In the multivariate analysis, older age (P ¼ .015), higher international normalized ratio (INR) (P ¼ .019), and acute liver failure (P ¼ .039) were independently associated with an adverse 1-month clinical outcome. On the other hand, older age (P ¼ .011) and acute kidney injury (P ¼ .031) at presentation were both related to worse 6-month outcome. For patients with ALF and AoCLF we did not observe the same differences. Conclusions. In this cohort, older age was the most important parameter defining 1- and 6-month survival, although higher INR and presence of ALF were important for 1-month survival and AKI for 6-month survival. No difference was observed between patients who underwent LT or did not have LT.